Drug
OPB-51602
OPB-51602 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 75.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
75.0%
Based on 3 completed trials
Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_1
4
100%
Phase Distribution
4
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Terminated(1)
Detailed Status
Completed3
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 1
Trials by Phase
Phase 14 (100.0%)
Trials by Status
completed375%
terminated125%
Recent Activity
0 active trials
Showing 4 of 4
terminatedphase_1
OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy
NCT02058017
completedphase_1
Phase I Study of OPB-51602 in Patients With Hematologic Malignancies
NCT01344876
completedphase_1
Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors
NCT01184807
completedphase_1
Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer
NCT01423903
Clinical Trials (4)
Showing 4 of 4 trials
NCT02058017Phase 1
OPB-51602 in Locally Advanced Nasopharyngeal Carcinoma Prior to Definitive Chemoradiotherapy
NCT01344876Phase 1
Phase I Study of OPB-51602 in Patients With Hematologic Malignancies
NCT01184807Phase 1
Phase 1, Dose-escalation Trial of OPB-51602 in Patients With Advanced Solid Tumors
NCT01423903Phase 1
Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4